Escalon Medical Corp NT 10-Q, filed Nov 15, 2023
Escalon Medical Corp (ESMC)
NT 10-Q
2023-11-15
For: 2023-09-30
View Original
Added on
October 17, 2026
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
SEC FILE NUMBER
0-20127
|
|
|
FORM 12b-25
NOTIFICATION OF LATE FILING
|
CUSIP NUMBER
296074305
|
☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR
For the Period Ended: September 30, 2023
☐ Transition Report on Form 10-K
☐ Transition Report on Form 20-F
☐ Transition Report on Form 11-K
☐ Transition Report on Form 10-Q
For the Transition Period Ended:
Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
|
Escalon Medical Corp.
|
|
Full Name of Registrant
|
|
Former Name if Applicable
|
|
435 Devon Park Drive, Suite 824
|
|
Address of Principal Executive Office (Street and Number)
|
|
Wayne, PA 19087
|
|
City, State and Zip Code
|
PART II - RULES 12b-25 (b) and (c)
If the subject report could not be filed without reasonable effort or expense and the Company seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
|
(a)
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
(b)
|
The subject annual report, semiannual report, transition report on Form 10-K, Form 20-F, Form 11-K,
|
|
|
☒
|
Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or
subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
(c)
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III - NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
The Registrant's Quarterly Report on Form 10-Q for the period ended September 30, 2023 could not be filed by the filing date without unreasonable effort and expense because the Registrant encountered delays in completing the financial statements
and finalizing the review of such financial statements for inclusion in the Form 10-Q associated with the implementation of a new accounting pronouncement and due to staffing limitations. The Registrant expects to file its Form 10-Q no later than
the extended due date.
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification:
|
Richard J. DePiano, Jr.
|
(610)
|
688-6830
|
|
(Name)
|
(Area code)
|
(Telephone Number)
|
(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company act of 1940 during the preceding 12 months or for such shorter
period that the Company was required to file such report(s) been filed? If the answer is no, identify report(s). ☒ Yes ☐ No
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or
portion thereof? ☐ Yes ☒ No
If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
|
Escalon Medical Corp.
|
|
|
Date: November 15, 2023
|
|
|
By: /s/ Richard J. DePiano, Jr.
|
|
|
Richard J. DePiano, Jr.
|
|
|
Chairman and Chief Executive Officer
|